A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1098 ◽

2019 ◽

Vol 25 (10) ◽

pp. 3193-3193

Author(s):

Nicholas Thatcher ◽

Jerome H. Goldschmidt ◽

Michael Thomas ◽

Michael Schenker ◽

Zhiying Pan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8046 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8046-8046 ◽

Author(s):

Egbert F. Smit ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

Ji Feng Feng ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-2702 ◽

2019 ◽

Vol 25 (7) ◽

pp. 2088-2095 ◽

Author(s):

Nicholas Thatcher ◽

Jerome H. Goldschmidt ◽

Michael Thomas ◽

Michael Schenker ◽

Zhiying Pan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.01.022 ◽

2017 ◽

Vol 12 (5) ◽

pp. 843-849 ◽

Author(s):

Maria Q. Baggstrom ◽

Mark A. Socinski ◽

Xiaofei F. Wang ◽

Lin Gu ◽

Thomas E. Stinchcombe ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Combination Chemotherapy ◽

Phase Iii ◽

Advanced Stage ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Phase III randomized double blind placebo controlled trial of cisplatin(P) and etoposide (E) plus megestrol acetate (M)/placebo in extensive stage small cell lung cancer (SCLC)

Lung Cancer ◽

10.1016/0169-5002(94)94116-5 ◽

1994 ◽

Vol 11 ◽

pp. 90 ◽

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Extensive Stage

Download Full-text

LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2122 ◽

2021 ◽

Vol 32 ◽

pp. S1321

Author(s):

Y-L. Wu ◽

Q. Zhou ◽

M. Chen ◽

O. Jiang ◽

D. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Unresectable Stage ◽

Phase Iii Study

Download Full-text

1339P Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: A randomized, double-blind, multicenter phase III study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1940 ◽

2021 ◽

Vol 32 ◽

pp. S1023

Author(s):

J. Wang ◽

R. Wang ◽

X. Dong ◽

Q. Chen ◽

Y. Yu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

377O A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.10.371 ◽

2020 ◽

Vol 31 ◽

pp. S1387

Author(s):

X. Ai ◽

Y. Pan ◽

J. Shi ◽

N. Yang ◽

C. Liu ◽

...

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps10142 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS10142-TPS10142

Author(s):

Li Zhang ◽

Ting Zhou ◽

Yuxiang Ma ◽

Yunpeng Yang ◽

Wenfeng Fang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1090830.544164 ◽

2007 ◽

Author(s):

Nico van Zandwijk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Iii ◽

Controlled Study ◽

Small Cell Lung ◽

Extensive Disease ◽

Double Blind ◽

Double Blind Placebo ◽

Response To Chemotherapy

Download Full-text